Of the overall oral antidiabetic drug sales in the key hospitals in China in 2018, slightly over half was contributed by acarbose and metformin. Beijing added a bunch of DDP-4 inhibitors like sitagliptin for reimbursement under government-backed insurance plans in 2017. With a drastic market growth in 2018, DDP-4 inhibitors were projected to take over acarbose as the leading revenue contributor in oral hypoglycemic medications in Chinese hospitals in 2030.
…. more: Statista.com (Quelle/Source)